This is an edited version of an article by Ariana Pelosi published in OncLive June 6, 2022.
Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.
Rucaparib (Rubraca) elicited a significant improvement in progression-free survival (PFS) outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups in both the primary and exploratory analyses of the ATHENA-MONO trial (NCT03522246). Specifically, the PARP inhibitor demonstrated improvements in both homologous recombination deficient (HRD)-positive and HRD-negative populations, findings from which were presented at the 2022 ASCO Annual Meeting....
“Patients with measurable disease at baseline have further tumor reduction with rucaparib. [Additionally], rucaparib safety profile is consistent with prior studies,” Bradley J. Monk, MD, FACS, FACOG, professor in the Division of Gynecologic Oncology at the University of Arizona College of Medicine, medical director of the Gynecologic Program at US Oncology Research Network, and lead investigator of this study, said during the presentation.
No comments:
Post a Comment